本研究的目的是评估口腔鳞状细胞癌（OSCC）患者及相关细胞系中细胞内和囊泡型LGALS3BP的表达，以探究其作为抗体药物联合物（ADC）治疗的潜在靶点。通过免疫组织化学、qRT-PCR、Western Blot分析和ELISA对OSCC患者组织样本以及一组OSCC细胞系进行了自由和囊泡型LGALS3BP的表达水平评估。结果显示，在OSCC患者组织的肿瘤细胞胞质中，LGALS3BP表达水平较高。高LGALS3BP表达水平与OSCC的侵袭性组织学特征之间存在显著相关性。对OSCC细胞系的生化分析显示，LGALS3BP在所有测试的细胞系中均有表达，并且在癌细胞源性细胞外囊泡中富集。此外，LGALS3BP高表达的HOC621和CAL27 OSCC细胞系对ADC荷载DM4具有高敏感性，IC50约为0.3 nM。本研究突出显示，在OSCC中LGALS3BP高表达，提示其作为潜在的诊断生物标志物和ADC治疗的治疗靶点。© 2023 The Authors. Oral Diseases由Wiley Periodicals LLC出版。

The aim of the present study was to evaluate the expression of intracellular and vesicular LGALS3BP in oral squamous cell carcinoma (OSCC) patients and available cell lines to explore its potential as a target for antibody-drug conjugate (ADC) therapy.Free and vesicular LGALS3BP expression levels were evaluated in cancer tissues from a cohort of OSCC patients as well as in a panel of OSCC cell lines through immunohistochemistry, qRT-PCR, Western Blot analysis, and ELISA.LGALS3BP resulted in being highly expressed in the cytoplasm of tumour cells in OSCC patient tissues. A strong correlation was found between high LGALS3BP expression levels and aggressive histological features of OSCC. Biochemistry analysis performed on OSCC cell lines showed that LGALS3BP is expressed in all the tested cell lines and highly enriched in cancer-derived extracellular vesicles. Moreover, LGALS3BP high-expressing HOC621 and CAL27 OSCC cell lines showed high sensitivity to the ADC-payload DM4, with an IC50 around 0.3 nM.The present study highlights that LGALS3BP is highly expressed in OSCC suggesting a role as a potential diagnostic biomarker and therapeutic target for ADC-based therapy.© 2023 The Authors. Oral Diseases published by Wiley Periodicals LLC.